Zenith Healthcare Q2 FY27 Results Board Meeting Today

Board meeting scheduled for October 28

Zenith Healthcare Ltd has informed the BSE that its board of directors will meet on Wednesday, October 28, 2026. The board is scheduled to consider and approve the company’s unaudited standalone financial results for the quarter ended September 30, 2026. It will also consider the unaudited results for the first half of FY27. The announcement places Zenith Healthcare among more than 140 companies scheduled to report September-quarter earnings on October 28. The company operates in the health care and life sciences sector and manufactures pharmaceutical formulations. Its products include tablets, capsules, oral liquids and injections across several therapeutic categories. The meeting is expected to take place at the company’s registered office in Ahmedabad. The company has not disclosed its September-quarter financial figures before the board meeting.

What the board will consider

The agenda specifically covers unaudited results for Q2 FY27, which represents the July-September 2026 period. It also covers the half-year period from April through September 2026. Such board meetings are part of the listed company disclosure process for quarterly financial reporting. Zenith Healthcare had previously submitted its June-quarter financial results to the exchanges on August 14, 2026. Its annual report for FY26 was filed on August 4, 2026. Before that, the board approved audited standalone results for the quarter and year ended March 31, 2026, at its May 29 meeting. The October meeting will therefore provide the next official update on the company’s operating and financial performance.

Trading window remains closed

Zenith Healthcare has said that the trading window for dealing in its securities is closed from October 1, 2026. The closure will continue until 48 hours after the declaration of the unaudited financial results. The step is in line with the SEBI (Prohibition of Insider Trading) Regulations. Trading-window restrictions are intended to prevent designated persons from trading while they may have access to unpublished price-sensitive information. Investors will need to wait for the board-approved exchange filing for the company’s Q2 and half-year figures. No earnings guidance or expected result range has been disclosed in the available announcement.

June quarter returned to profit

Zenith Healthcare reported a recovery in profitability in Q1 FY27. Standalone revenue for the June 2026 quarter was ₹3.50 crore, up 28.8% sequentially and 5.6% from the corresponding quarter a year earlier. Net profit stood at ₹0.14 crore, compared with a loss in the preceding March quarter. A separate company update reported Q1 FY27 profit at ₹13.62 lakh, equivalent to about ₹0.14 crore. Operating profit margin was reported at 5.11%. This marked an improvement from the negative margin recorded in the March 2026 quarter. The June-quarter result is the immediate comparison point for investors assessing the September-quarter disclosure.

FY26 ended with pressure on operations

The March 2026 quarter had been weak for the company. Zenith Healthcare reported revenue of ₹2.62 crore in Q4 FY26, down 23.62% year-on-year. It posted a net loss of ₹0.34 crore, against a profit of ₹0.11 crore in the corresponding quarter of the previous year. Operating margin was negative 17.56% in Q4 FY26, compared with a positive 0.87% a year earlier. For the full year ended March 2026, total revenue was ₹10.52 crore. Operating loss for the year was ₹0.39 crore and the operating margin was negative 3.7%. These figures show why the June-quarter move back to profit will be closely followed in the upcoming release.

Key reported financial data

Pharmaceutical formulation business context

Zenith Healthcare manufactures pharmaceutical formulations in multiple dosage forms, including tablets, capsules, oral liquids and injections. Its portfolio covers antibiotics and anti-infectives, cardiovascular medicines, central nervous system products, gastrointestinal treatments, respiratory products, nutrition, skin care and endocrine therapies. The company was founded on November 15, 1994, and is headquartered in Ahmedabad. Mahendra C Raycha is listed as chairperson. The company reported 42 employees in the provided company information. Its fiscal year ends in March. The September-quarter results will offer a current measure of how this formulation business performed after the June-quarter improvement.

What investors may assess in Q2 FY27

The main focus will be whether Zenith Healthcare sustained the revenue improvement recorded in Q1 FY27. Investors may also assess whether the positive operating margin in the June quarter continued into the September quarter. Profitability is important because FY26 closed with an operating loss and Q4 FY26 included a net loss. The half-year figures will provide a broader view than a single quarter by combining the April-June and July-September periods. Revenue, expenditure, operating performance and net profit or loss will be key items in the board-approved filing. The announcement itself does not provide a basis for estimating the company’s Q2 result. Any assessment of performance should therefore rely on the formal exchange disclosure after the meeting.

Next official disclosure

Zenith Healthcare’s October 28 board meeting is the scheduled event for the company’s Q2 and first-half FY27 financial update. The board will consider the unaudited results for the quarter and half year ended September 30, 2026. The trading window will reopen only after 48 hours have passed from the results declaration. The company’s June-quarter return to profit followed a difficult March quarter and a loss-making FY26 operating performance. The upcoming filing will show whether that June-quarter improvement was maintained. Investors should track the BSE disclosure for the final revenue, profitability and margin figures approved by the board.